Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study
Sorafenib has been widely used to treat unresectable hepatocellular carcinoma (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with well-preserved liver function. We evaluated the overall survival (OS) and tolerance to sorafenib in a large cohort of Child-Pugh B (CP-B) HCC patients as compared to CP-A HCC patients. We prospectively studied 130 patients with advanced HCC who started sorafenib between January 2011 and December 2015. Patients were classified as CP-A (n = 65) or CP-B (n = 65). The average OS for all 130 patients was 10 months. CP-A patients had a median survival rate significantly longer than CP-B patients: 12 months vs. 6 months. The OS found in our group of CP-B patients was 6.5 months, which is higher than that found in most studies done so far. When stratified, our CP-B patients had better OS than ever reported. The dose of the drug was interrupted due to adverse events (AEs) in 38 (29%) of the patients, of whom 20 (30%) were CP-A patients and 18 (28%) were CP-B patients. This real-life cohort of CP-B HCC patients treated with sorafenib had a higher survival than that described in the literature, with a satisfactory safety profile. Despite the high prevalence of severe AEs in CP-B patients, there were fewer treatment interruptions in this group, indicating that Child-Pugh B patients can tolerate treatment and may benefit from sorafenib.
KeywordsChild-Pugh B Hepatocellular carcinoma Sorafenib Child-Pugh A
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The study protocol was approved by the local Ethics Committee and all patients signed a consent form.
- 5.Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo- controlled trial. Lancet Oncol 10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7 CrossRefPubMedGoogle Scholar
- 7.Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084991 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.U.S. Department of health and human services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) [cited 2018 Jun 1]; Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf
- 12.Wada Y, Takami Y, Tateishi M et al (2016) The efficacy of continued sorafenib treatment after radiologic confirmation of progressive disease in patients with advanced hepatocellular carcinoma. PLoS One 11(1):e0146456. https://doi.org/10.1371/journal.pone.0146456 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Chiu J, Tang YF, Yao T et al (2012) The use of single-agent Sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying child-Pugh B liver cirrhosis. A retrospective analysis of efficacy, safety, and survival benefits. Cancer 118(21):5293–5301. https://doi.org/10.1002/cncr.27543 CrossRefPubMedGoogle Scholar
- 25.Reig M, Lope CR, Llarch N et al (2013) Dermatologic adverse events within the first 60 days of sorafenib treatment are associated with better overall survival (OS) in patients with hepatocellular carcinoma (HCC). J Hepatol 58(Suppl. 1):S63–S227. https://doi.org/10.1016/S0168-8278(13)60269-X https://www.journal-of-hepatology.eu/article/S0168-8278(13)60269-X/abstract CrossRefGoogle Scholar